Low-tech solutions for the COVID-19 supply chain crisis

Armani, Andrea M.; Hurt, Darrell E.; Hwang, Darryl; McCarthy, Meghan C; Scholtz, Alexis

doi:10.1038/s41578-020-0205-1

Cited by 101 publications

(79 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their study focused on comparing the impact of the disruption caused by the pandemic on product and service businesses in order to develop a crisis-management model [11]. The impact of low-tech manufacturing solutions argued that solutions need to coalesce around approved designs to have a real impact [12]. Other studies examine manufacturing from the perspective of supply chain resilience and risks [13,14].…”

Section: Manufacturing and The Pandemicmentioning

confidence: 99%

“…A UNIDO report also observes several of these barriers [16]. Beyond these identified barriers, current literature argues that firms which operate or support their operations with servitized business models-including leasing and renting of products-are more resilient than traditional models purely focused on selling products [12]. Fluctuating demand and supply was also identified as a barrier by respondents.…”

Section: Manufacturing and Repurposing Barriersmentioning

confidence: 99%

See 1 more Smart Citation

Manufacturing in the Time of COVID-19: An Assessment of Barriers and Enablers

Okorie

Subramoniam

Charnley

et al. 2020

IEEE Eng. Manag. Rev.

131

View full text Add to dashboard Cite

Pandemics and other forms of epidemic outbreaks are a unique case of manufacturing risk typified by high uncertainty, increasing propagation and long-term disruption to manufacturers, supply chain actors as well as the end-users and consumers. For manufacturing the COVID-19 disruption scope has been largely twofold ; an endogenous disruption of manufacturing processes and systems as well as extreme shifts in demand and supply caused by exogenous supply chain disruption. Existing literature on disruptions in manufacturing suggests that pandemics are qualitatively different from typical disruptions. There is no literature available to manufacturing practitioners that identify the barriers and enablers of manufacturing resilience, especially with regards to pivoting of the manufacturing sector in response to a pandemic. This study draws on an extensive survey collected during the COVID-19 pandemic. The respondents were employees of manufacturing firms in all regions of the world who had engaged in manufacturing during the pandemic or had opted out from manufacturing due to various identified reasons. By collating their responses, we offer to practitioners and policymakers an analysis for identifying a bestpractice framework for pivoting successfully as a response to major manufacturing disruptions.

show abstract

Section: Manufacturing and The Pandemicmentioning

confidence: 99%

Section: Manufacturing and Repurposing Barriersmentioning

confidence: 99%

Manufacturing in the Time of COVID-19: An Assessment of Barriers and Enablers

Okorie

Subramoniam

Charnley

et al. 2020

IEEE Eng. Manag. Rev.

131

View full text Add to dashboard Cite

show abstract

“…The narrative commentary presented below takes into account scientific articles [13,17,[20][21][22][23], official publications of Food and Drug Agency (FDA) [4,24], European Commission [25], United Nations [26] and national regulatory agency reports in native languages [27,28].…”

Section: Resultsmentioning

confidence: 99%

Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study

et al. 2020

View full text Add to dashboard Cite

Background The world is facing an unprecedented outbreak affecting all aspects of human lives which is caused by the COVID-19 pandemic. Due to the virus novelty, healthcare systems are challenged by a high rate of patients and the shortage of medical products. To address an increased need for essential medical products, national authorities, worldwide, made various legislative concessions. This has led to essential medical products being produced by automotive, textile and other companies from various industries and approved under the emergency use authorizations or legal concessions of national regulatory bodies. This paper presents a narrative commentary of the available documentation on emergency use authorizations and legal concessions for medical products during COVID-19 pandemic. Methodology The basis for narrative commentary includes scientific articles published in Web of Science, Scopus, PubMed and Embase databases, official publications of international organizations: Food and Drug Agency (FDA), World Health Organisation (WHO), World Bank and United Nations (UN), and national regulatory agency reports in native languages (English, German, Bosnian, and Croatian) published from November 1, 2019 to May 1, 2020. This paper focuses on three types of essential medical products: mechanical ventilators, personal protective equipment (PPE) and diagnostic tests. Evidence-informed commentary of available data and potential identified risks of emergency use authorizations and legal concessions is presented. Discussion It is recognized that now more than ever, raising global awareness and knowledge about the importance of respecting the essential requirements is needed to guarantee the appropriate quality, performance and safety of medical products, especially during outbreak situation, such as the COVID-19 pandemic. Emergency use authorizations for production, import and approval of medical products should be strictly specified and clearly targeted from case to case and should not be general or universal for all medical products, because all of them are associated with different risk level. Conclusion Presented considerations and experiences should be taken as a guide for all possible future outbreak situations to prevent improvised reactions of national regulatory bodies.

show abstract

“…printed components, and ventilator sharing [9][10][11][12][13]. At the very beginning, the team decided that the Vent-I should become available in large quantities in a very short time and that the functionality and specifications should be based on what was requested by the doctors involved.…”

Section: Development Of the Vent-imentioning

confidence: 99%

Lessons Learned from Rapid Development of CPAP Ventilator Vent-I during Covid-19 Pandemic in Indonesia

Hidayat

Halid²,

Dirgantara

et al. 2020

J. Eng. Technol. Sci.

View full text Add to dashboard Cite

 This paper describes the process of a rapid development of the CPAP ventilator 'Vent-I' during the COVID-19 pandemic using appropriate technology and locally available components.  It was found that noble values and spirit are very important success factors, i.e. gotong royong, social entrepreneurship, pioneering and volunteerism.  Public trust was a very valuable social capital during the development and crowdfunding.  Collaboration between academic institutions, industry and the relevant authority from the very beginning will speed up the development and certification process.

show abstract

Low-tech solutions for the COVID-19 supply chain crisis

Cited by 101 publications

References 5 publications

Manufacturing in the Time of COVID-19: An Assessment of Barriers and Enablers

Manufacturing in the Time of COVID-19: An Assessment of Barriers and Enablers

Risks of emergency use authorizations for medical products during outbreak situations: a COVID-19 case study

Lessons Learned from Rapid Development of CPAP Ventilator Vent-I during Covid-19 Pandemic in Indonesia

Contact Info

Product

Resources

About